Biocon limited, Amylin pharmaceuticals enter global development agreement.Byline: ANI Bangalore/ California Sep 11(ANI/Business Wire India): Biocon, Limited (NSE NSE - Network Software Environment: a proprietary CASE framework from Sun Microsystems. : BIOCON) and Amylin Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. Currently, Amylin produces two drugs, Symlin (pramlintide acetate) and Byetta (exenatide). Amylin also is working on producing a drug based on Leptin. , Inc. (Nasdaq: AMLN) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones peptide hormones (pepˑ·tīd hōrˑ·mōnz), n.pl into a single molecular entity. Under the terms of the Development and Commercialization Agreement, Amylin will provide expertise in peptide hormone Peptide hormones are a class of peptides that are secreted into the blood stream and have endocrine functions in living animals. Like other proteins, peptide hormones are synthesized from amino acids according to an mRNA template, which is itself synthesized from a DNA development, particularly in the area of phybrid technology, as well as metabolic disease metabolic disease, n a disorder that causes dysfunction of the metabolic action of the body, resulting in loss of control of homeostasis. paraneoplastic syndrome therapeutics. Biocon will utilize its expertise in recombinant microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. expression to manufacture the compound and also leverage its experience in pre-clinical and clinical development of diabetes products. "This agreement fully leverages the synergistic capabilities of the two companies," said Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon, Ltd. "Amylin's knowledge of peptide therapeutics and their leadership in the diabetes market, paired with Biocon's capabilities in process development, manufacturing and clinical development, provides this global program with the potential to effectively bring a novel therapy to patients living with diabetes." "This program could unleash the potential of cutting-edge peptide science to transform the lives of patients with diabetes," said Daniel M. Bradbury, President and Chief Executive Officer, Amylin Pharmaceuticals. "We are pleased to work with Biocon, a biologics innovator and world-class manufacturing expert, and look forward to collaborating with them on this exciting program." Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. (ANI) Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency. (ANI) - All Rights Reserved. Provided by Syndigate.info an Albawaba.com company |
|
|||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion